Lindsay Rocco | Elixir Health Public Relations |
Matthew Pauls | President and CEO |
Fred Cohen | Chief Medical Officer |
Brian Davis | Chief Financial Officer. |
Hartaj Singh | Oppenheimer & Co. |
Annabel Samimy | Stifel |
Liisa Bayko | JMP Securities |
Esther Hong | Janney |
Elemer Piros | Cantor Fitzgerald |
Good day, ladies and gentlemen, and welcome to Strongbridge Biopharma Earnings Results and Second Quarter Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Lindsay Rocco, Elixir Health Public Relations.
You may begin.
Thank you and good morning everyone.
We are pleased that you could join us today to discuss the positive results from the pivotal phase III SONICS study of RECORLEV second quarter 2018 earnings and corporate highlights.